

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

End of Result Set

☐ [Generate Collection](#) [Print](#)

L7: Entry 4 of 4

File: DWPI

May 3, 1984

DERWENT-ACC-NO: 1984-115489

DERWENT-WEEK: 198419

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Calcium antagonists verapamil and gallopamil admin. - via oral, naso-pharyngeal or rectal mucosa e.g. using buccal or sub:lingual tablets

INVENTOR: FROMMING, K H; NEUGEBAUER, G ; RIETBROCK, N ; WOODCOCK, B G

PATENT-ASSIGNEE:

ASSIGNEE

CODE

BASF AG

BADI

PRIORITY-DATA: 1982DE-3240156 (October 29, 1982), 1983DE-3338978 (October 27, 1983)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

DE 3338978 A

May 3, 1984

015

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

DE 3338978A

October 27, 1983

1983DE-3338978

INT-CL (IPC): A61K 9/20; A61K 31/27

ABSTRACTED-PUB-NO: DE 3338978A

BASIC-ABSTRACT:

The use of verapamil (I) and gallopamil (II) and their physiologically tolerable salts for resorptive use as cardiovascular agents in the mucous membranes of the mouth, the naso-pharyngeal tract and the rectum is new. The following formulations of (I) or (II) or one of their physiologically tolerable acid addition salts are new: (A) sublingual or buccal tablets contg. 5-25 mg (I) or 3-15 mg (II) or an equivalent amount of one of their physiologically tolerable acid addition salts; (B) capsules for chewing or biting contg. 5-25 mg (I) or 3-15 mg (II) or an equivalent amount of one of their physiologically tolerable acid addition salts; (C) mouth sprays for absorption via the oral mucous membranes, nasal sprays for absorption via the naso-pharyngeal mucous membranes, rectal suppositories, rectal capsules, rectal micro-enemas, osmotic pumps for rectal use, and snuff powder for absorption via the naso-pharyngeal mucous membranes, contg. (I) or (II) or one of their physiologically tolerable acid addition salts.

Use of a mode of administration which bypasses hepatic metabolism gives a more rapid onset of calcium-antagonistic cardiovascular activity, and activity is 2-8 times greater than after oral administration.

TITLE-TERMS: CALCIUM ANTAGONIST VERAPAMIL GALLOPAMIL ADMINISTER ORAL PHARYNGEAL RECTUM MUCOUS BUCCAL SUB LINGUAL TABLET

DERWENT-CLASS: B07

CPI-CODES: B10-A15; B12-E01; B12-F01; B12-G01;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

G015 G017 G019 G100 H1 H103 H181 H5 H543 H8
K0 L1 L145 M210 M211 M272 M273 M281 M283 M312
M315 M321 M332 M333 M342 M343 M371 M373 M391 M414
M431 M510 M520 M532 M540 M640 M650 M782 M903 P520
P522 P617 R012 R031 R036 R037 R038

Chemical Indexing M6 *02*

Fragmentation Code

M903 P520 P522 P617 R012 R031 R036 R037 R038 R111
R200 R252 R280 R290

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1984-048549

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)